Haemonetics (HAE) Gross Margin (2009 - 2026)

Haemonetics' Gross Margin history runs 18 years deep, the most recent figure standing at 57.23% for Q1 2026.

• On a quarterly basis, Gross Margin fell 117.0% year-over-year to 57.23% in Q1 2026; TTM through Mar 2026 was 59.04%, a 400.0% increase from a year earlier, with the FY2026 full-year figure at 59.04%, up 400.0% from the prior year.
• Gross Margin slipped to 57.23% in Q1 2026 per HAE's latest filing, from 59.71% in the prior quarter.
• Across five years, Gross Margin topped out at 59.82% in Q2 2025 and bottomed at 51.24% in Q1 2024.
• The 5-year median for Gross Margin is 53.66% (2023), against an average of 54.64%.
• Across the five-year window, Gross Margin soared 1508 bps in 2022 and tumbled 169 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 51.98% in 2022, then climbed by 2 bps to 52.9% in 2023, then gained by 5 bps to 55.53% in 2024, then grew by 8 bps to 59.71% in 2025, then fell by 4 bps to 57.23% in 2026.
• Per Business Quant, the three latest HAE Gross Margin figures stand at 57.23% (Q1 2026), 59.71% (Q4 2025), and 59.5% (Q3 2025).